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Background: Speed Leish K® is used as a serological screening test for Leishmania infection prior to vaccination.
Limited comparative serological studies with Speed Leish K® have been performed. The aim of this study was to
evaluate the diagnostic performance of four commercially available serologic tests including ELISAs (Leiscan®, ID
Screen® and Leishmania 96®), a rapid test (Speed Leish K®) and an in-house IFAT for the detection of specific
antibodies against Leishmania infantum antigen in dogs in different states of infection.
Methods: Sick infected dogs (n = 36), healthy infected dogs (n = 18), L. infantum seropositive dogs with low to high
levels of antibodies (n = 53), dogs seropositive to other pathogens (to evaluate cross reaction) (n = 14) and
uninfected dogs from a non-endemic area (n = 50) and from an endemic area (n = 32) were analysed by the
serological methods mentioned above.
Results: The sensitivity was as follows: ID Screen® (0.953), Leiscan® and Leishmania 96® (0.925), IFAT (0.869) and
Speed Leish K® (0.636). The maximum specificity (1.000) was attained for all diagnostic tests except the Leishmania
96® (0.896) and IFAT (0.917). The accuracy was as follows: ID Screen® (0.975), Leiscan® (0.961), Leishmania 96® (0.911),
IFAT (0.892) and Speed Leish K® (0.808). In relation to the area under the ROC curve (AUC-ROC), the maximum value
was attained with the ID Screen® (0.993) closely followed by Leiscan® (0.990), then, Leishmania 96® (0.962), IFAT
(0.926) and Speed Leish K® (0.818). For the Kappa index, the best result was obtained by the ID Screen® (0.951)
followed by Leiscan® (0.921), Leishmania 96® (0.822), IFAT (0.783) and Speed Leish K® (0.622). Statistically significant
differences were found between the AUC-ROC of quantitative serological tests and the only qualitative rapid test
evaluated. There were also statistically significant differences between AUC-ROC of the ELISAs (ID Screen® and
Leiscan®) and IFAT.
Conclusions: Leiscan® and ID Screen® had superior diagnostic performance measures than IFAT and all quantitative
serological tests were superior when compared to Speed Leish K®. Thus, Speed Leish K® may be considered a less
valuable screening test prior to vaccination as it may result in vaccination of seropositive dogs and in some cases
seropositive sick dogs.
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Canine leishmaniosis (CanL) is a vector-borne zoonotic
disease caused by Leishmania infantum, endemic in more
than 70 countries in the world. It is present in regions of
southern Europe, Africa, Asia, South and Central America
[1]. Dogs are the main reservoir for this infection and
sandflies are the only arthropods that are adapted to its
biologic transmission. However, other non-sandfly proven
ways of infection include blood transfusion, vertical and
venereal transmission [2,3].
In endemic areas, the prevalence of L. infantum infection
in dogs is greater than the seroprevalence and the preva-
lence of clinical disease [1,4]. Therefore, CanL is a good ex-
ample of a disease in which infection does not equal
clinical illness due to the high prevalence of persistent sub-
clinical infection. In addition, clinical illness varies from
self-limiting disease to very severe fatal disease. Clinical sta-
ging of CanL includes four stages of severity of illness based
on clinical signs, clinicopathological abnormalities and ser-
ology. For these reasons, diagnosis of this parasitic infection
and its clinical manifestations can be complex [2,3].
The biggest obstacle in the evaluation of diagnostic tests
for CanL is that there is not a definitive diagnostic refer-
ence test or gold standard with which to compare the al-
ternative diagnostic assays. There is no diagnostic test
with 100% sensitivity and 100% specificity for detection of
L. infantum infection and therefore it is essential to know
the terms and limitations of each diagnostic test, and to
select the best tests for the purpose of the diagnosis [3].
The methods used for diagnosis of dogs with suspected
clinical leishmaniosis include the detection of amastigotes
in stained cytological smears of aspirates or histopatho-
logical sections from several tissues. Immunohistochemi-
cal staining of tissue sections is employed to enhance the
visualization of the parasite. The isolation in culture of
parasites from infected tissues is not suitable for rapid
diagnosis. However, the most useful diagnostic approaches
for investigation of infection in sick and healthy sub-
clinically infected dogs include: (1) detection of specific
serum anti-leishmanial antibodies by quantitative sero-
logical techniques and (2) demonstration of the parasite
DNA in tissues by applying molecular techniques. High
antibody levels are usually associated with disease and a
high parasite density and, for this reason, they are conclu-
sive of a diagnosis of leishmaniosis. However, the presence
of lower antibody levels is not necessarily indicative of pa-
tent disease and needs to be confirmed by other diagnostic
methods such as polymerase chain reaction (PCR), cy-
tology or histology [2,3].
As mentioned above, serological methods are the most
common diagnostic techniques used for the diagnosis of
CanL. A vaccine, CaniLeish® (Virbac, France), has recently
been licensed in Europe for the prevention of CanL in
seronegative dogs. The manufacturers recommend the useof a rapid serological test, Speed Leish K®, prior to vaccin-
ation as a screening test for Leishmania infection [5].
However, so far, only one comparative serological study
with this rapid test has been published and therefore, the
information about the diagnostic performance of this
assay is extremely limited [6]. Moreover, there are several
different commercial serologic tests currently available,
however their effectiveness might vary widely and there-
fore affects the ability to reach a correct diagnosis.
For these reasons, the aim of this study was to evaluate
the diagnostic performance of four commercially available
serologic assays including three quantitative commercial
enzyme-linked immunosorbent assay (ELISA) tests (Leis-
can®, ID Screen® and Leishmania 96®), one qualitative com-
mercial rapid test (Speed Leish K®) and one quantitative
in-house indirect fluorescent antibody test (IFAT) for the
detection of specific antibodies against the antigen of L.
infantum in dogs with different states of infection. In the
present manuscript, the diagnostic performance of quanti-




Three commercial ELISAs and one immunochromato-
graphic test were evaluated. The ELISA based quantitative
assays were: the Leiscan® Leishmania ELISA Test (Esteve
Veterinaria, Laboratorios Dr. Esteve SA, Spain), ID Screen®
Leishmaniasis Indirect Test (VET-Innovate ID Diagnos-
tics, France) and Leishmania 96® (Agrolabo S.p.A., Italy).
The immunochromatographic based qualitative assay was:
Speed Leish K® (Virbac, France). Assays were carried out ac-
cording to the manufacturer’s instructions. In the commer-
cial ELISA tests, all samples were analyzed in duplicate.
In house techniques
The in house IFAT was performed at the Istituto Zoo-
profilattico Sperimentale delle Venezie (Padova, Italy)
and is described in the Manual of the World Organisa-
tion for Animal Health [7]. The antigen was prepared
from promastigotes of L. infantum from Istituto Super-
iore di Sanità (Italy). Anti-Leishmania antibodies were
detected using anti-dog IgG conjugated to fluorescein
isothiocyanate (Sigma-Aldrich, USA). Samples were clas-
sified as positive if promastigote cytoplasmatic or mem-
brane fluorescence was observed at a serum dilution of
1:40 or higher.
The Universitat Autònoma de Barcelona (UAB) in
house ELISA was performed on sera of all dogs studied
as the reference quantitative serological technique as
previously described [4,8-10], with some modifications.
This UAB in house ELISA has good diagnostic perform-
ance [4,8-10]. Briefly, dog sera were diluted to 1:800 and
incubated in sonicated crude L. infantum antigen-coated
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washed with 0.05% Tween 20 in phosphate-buffered saline
(PBS) and incubated with Protein A conjugated to horse-
radish peroxidase (1:30,000 dilution; Sigma-Aldrich) for 1
hour at 37°C. Plates were washed again with 0.05% PBS-
Tween 20. The plates were developed by adding the
substrate solution ortho-phenylene-diamine and stable
peroxide substrate buffer (Thermo scientific). The reaction
was stopped with 50 μl of 2.5 M H2SO4. Absorbance values
were read at 492 nm in an automatic microELISA reader
(ELISA Reader Anthos 2001). All plates included the serum
from a sick dog with a confirmed infection as positive con-
trol (calibrator) and serum from a healthy dog as a negative
control and all samples were analyzed in duplicate. The re-
sult was quantified as ELISA units (EU) related to a positive
canine serum used as a calibrator and arbitrarily set at 100
EU. The cutoff was established at 35 U (mean + 4 SD of
values from 80 dogs from non- endemic area). Sera were
classified as being high positive, when having a positivity
percentage (% p) equal or higher than 300% (≥300%),
medium positive were classified as % p equal or higher
than 150% (>150%) and less than 300% (<300%). Finally,
low positive were sera from those dogs with % p lower
than 150% (<150%) and higher than 35%.
Study location and dogs
The subjects involved in the study were two hundred
three dogs from Italy, United Kingdom, Cyprus and
Spain. All sera samples were collected between 2011 and
2012. All dogs were classified as positive (infected) or
negative (not infected) to L. infantum by serological and/
or molecular diagnostic techniques. Out of 203 dogs stud-
ied, 107 were classified as positive (infected) and the rest
were classified as negative to infection.
Dogs were allocated into sick or clinically healthy in-
fected groups based on clinical history, a complete phys-
ical examination to reveal the presence of clinical signs
consistent with the disease, evidence of clinicopathological
abnormalities consistent with leishmaniosis and a positive
quantitative serology and/or molecular test for L. infan-
tum infection [3]. Sera samples were taken for diagnostic
purposes and, therefore, ethical approval was not needed.
Clinically sick infected dogs
Sera samples from dogs with clinical leishmaniosis (n =
36) came from Cyprus and Italy. Sick dogs from Cyprus
(n = 17) were characterized based on presence of clinical
signs at physical examination and/or clinicopathologic ab-
normalities consistent with clinical leishmaniosis [2,3] as
well as having a positive result by Leishmania real-time
PCR [11] in blood and/or conjunctival swabs and a high
positive antibody level using two different quantitative
ELISA serological tests [8,12]. Sick dogs from Italy (n =
19) came from the San Marco Veterinary Hospital(Padova, Italy). These dogs were diagnosed based on
presence of clinical signs at physical examination and/
or clinicopathologic abnormalities consistent with clin-
ical leishmaniosis [2,3] based on CBC, serum biochemistry
profile, and urianalysis as well as having a positive result
by Leishmania real-time PCR [9] in blood samples and/or
bone marrow and a high positive (n = 15) and medium
positive (n = 4) antibody level using UAB in house ELISA
[8]. Based on the LeishVet guidelines for staging disease
[2,3], all dogs in the group were stage II or above. There-
fore, all dogs presented at least moderate disease.
Clinically healthy infected dogs
Dogs classified as clinically healthy infected animals were
from Cyprus (n = 6) and Spain (n = 12), characterized by
the absence of clinical signs based on physical examination
and absence of laboratory abnormalities based on CBC
and serum biochemistry profile, and with a positive sero-
logical result based on UAB in house ELISA [8]. Dogs
were classified as high positive (n = 4), medium positive
(n = 3) and as low positive (n = 11) based on UAB in house
ELISA [8]. In the case of the six dogs from Cyprus, they
were also positive with Leishmania real-time PCR [11] of
blood and/or conjunctival swabs.
Seropositive infected dogs with low to high levels of
anti-Leishmania antibodies
A total of 53 dogs were studied, no clinical or clinicopath-
ological information was available for these dogs and they
were allocated to this group based on anti-Leishmania
antibody levels detected by UAB in house ELISA [8].
These serum samples were collected from owned dogs in
several Italian veterinary clinics and submitted to the San
Marco Veterinary Laboratory (Padova, Italy) between
2011 and 2012 in order to establish the serological diagno-
sis of L. infantum infection. Dogs were classified as high
positive (n = 34), medium positive (n = 14) and as low
positive (n = 5) based on UAB in house ELISA [8].
Uninfected dogs from non-endemic areas
Fifty canine sera samples from the Queen Mother Hospital
at the Royal Veterinary College (RVC, University of London)
were sent to the diagnostic laboratory at RVC for serum
biochemical profile or other diagnostic tests such as hormo-
nal assays or serologic tests were included in this study.
All these residual sera samples were negative for L.
infantum based on UAB in house ELISA [8].
Uninfected dogs from endemic area
Thirty two sera samples from clinically healthy dogs
from an endemic area (Cyprus), with a negative result
for two quantitative in house ELISAs [8,12] and Leish-
mania real-time PCR in blood and/or conjunctival
swabs [11] were studied.
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(to evaluate cross reaction)
Fourteen samples from the San Marco Veterinary Labora-
tory with a positive serological IFAT result for different
pathogens: Ehrlichia canis (n = 5, antibody titers ranging
from 1:640 to 1:1280), Toxoplasma gondii (n = 1, antibody
titer of 1:640), Rickettsia conorii (n = 7, antibody titers ran-
ging between 1:640 and 1:1280) and Anaplasma phagocy-
tophilum (n = 1, an antibody titer of 1:640) were studied.
All these samples were negative for L. infantum by the
quantitative UAB in house ELISA [8].
Statistical analysis
Performance measures analysed for each test were: sen-
sitivity, specificity, accuracy, area under curve-receiver
operating characteristic (AUC-ROC), Kappa index and
the Youden index [10].
The agreement between serological diagnostic techniques
and several groups of dogs studied was evaluated by the
use of kappa index. The kappa agreement between sero-
logical diagnostic techniques was determined as follows: no
agreement (k < 0), slight agreement (0 < k <0.2), fair agree-
ment (0.2 < k <0.4), moderate agreement (0.4 < k <0.6), sub-
stantial agreement (0.6 < k <0.8) and almost perfect
agreement (k >0.8).
In order to better characterize the serological test
studied, the Youden index [10] was calculated. The You-
den index measures the efficiency of a diagnostic test
using a single value, replacing the dual form sensitivity-
specificity in such a way that a single index is obtained.
This ratio can vary from −1 to 1. If the Youden index is
less or equal to 0, the diagnostic test analyzed has no in-
formative value. Thus, a diagnostic test is considered
good when the Youden index approaches 1.
Other parameters analyzed were the positive predictive
value (PPV) and negative predictive value (NPV). Both
parameters are performance measures of the effective-
ness of a diagnostic test, dependent on the prevalence of
disease in a population. The seroprevalence in dogs liv-
ing in the Mediterranean basin can range from 5 to 30%
depending on the region studied [3]. In this study, the
PPV and NPV were calculated taking into account the
sensitivity and specificity obtained for each of the sero-
logical tests evaluated and with respect to dogs from en-
demic areas with varying seroprevalence: areas with low
seroprevalence (10%) [13] and endemic areas with mod-
erate to high seroprevalence (25%) [14].
For the ROC curve analysis, a confidence interval (CI)
(95%) for the area under receiver-operating curve was
produced for each test analyzed. A significance statistical
level α = 0.05 was used for the confidence interval at
95% (CI) with lower and upper limits acceptable for CI.
Swets [15] established three categories to determine the
accuracy of a diagnostic technique based on the AUC-ROC. These categories are: high accuracy (0.9 < AUC-
ROC ≤ 1), moderate accuracy (0.7 < AUC-ROC ≤ 0.9) and,
finally, low accuracy (0.5 < AUC-ROC ≤ 0.7).
The IBM SPSS statistics version 20 program was used.
A p value < 0.05 was considered significant.
Results
Measures of diagnostic performance
The results of the diagnostic performance measures of
the serological tests compared are described in Tables 1
and 2. The sensitivity of the serological tests were as fol-
lows; ID Screen® (0.953), Leishmania 96® and Leiscan®
(0.925), IFAT (0.869) and Speed Leish K® (0.636). Specifi-
city was optimal (1.000) for several tests: ID Screen®,
Leiscan® and Speed Leish K®, followed by IFAT (0.917)
and finally the Leishmania 96® (0.869).
Accuracy was as follows: ID Screen® (0.975), Leiscan®
(0.961), Leishmania 96® (0.911), IFAT (0.892) and Speed
Leish K® (0.808).
In relation to Kappa agreement for all serological tech-
niques analyzed, there was almost perfect agreement be-
tween the ID Screen®, Leiscan® and Leishmania 96® and
dogs with different states of infection (K = 0.951; K =
0.921, K = 0.822; respectively). Substantial agreement
was found between IFAT and dogs with different states
of infection (K = 0.783) and between the Speed Leish K®
and dogs with different states of infection (K = 0.622).
Using the Youden index to measure test efficiency, the
highest efficiency was obtained by the ID Screen®
(0.953), then Leiscan® (0.925), Leishmania 96® (0.821),
IFAT (0.786) and, finally, the Speed Leish K® (0.636).
In a high seroprevalence setting (25%), the PPV was
optimal (1.000) for all tests except Leishmania 96®
(0.748) and IFAT (0.777). However, in a low seropreva-
lence setting (10%) different tests performed better for
PPV; with the ID Screen®, Leiscan® and Speed Leisk K®
(1.000), superior to IFAT (0.538) and, finally, the Leish-
mania 96® (0.497).
With relation to the NPV in high seroprevalence areas
(25%), negative NPV was optimal for the ID Screen®
(0.985), followed by Leiscan® (0.976), Leishmania 96®
(0.973), and IFAT (0.955) and, finally, the Speed Leish K®
(0.892). A similar but not identical profile was seen at
low seroprevalence settings (10%) for NPV: ID Screen®
(0.995), Leiscan® (0.992), Leishmania 96® (0.991), IFAT
(0.984) and Speed Leish K® with the lowest value (0.961)
(Table 2).
ROC Curve analysis
AUC-ROC analyses and confidence intervals (CI, 95%)
obtained from the curve allowed comparison between
the different serological tests. The maximum value was
reached for the ID Screen® (0.993 95% CI: 0.983 to
1.000), closely followed by Leiscan® (0.990, 95% CI: 0.975
Table 1 Results of measures of diagnostic performance of serological tests studied based on manufacturer’s
recommendations and based on ROC cut-off values
Measures of diagnostic performance
ID screen®a ID screen®b Leiscan®a Leiscan®b Leishmania 96®a Leishmania 96®b IFATa IFATb Speed Leish K®
Sensitivity 0.953 0.963 0.925 0.953 0.925 0.832 0.869 0.813 0.636
Specificity 1.000 1.000 1.000 1.000 0.896 0.980 0.917 0.990 1.000
Accuracy 0.975 0.980 0.961 0.975 0.911 0.902 0.892 0.897 0.808
Kappa index 0.951 0.961 0.921 0.951 0.822 0.804 0.783 0.795 0.622
Youden index 0.953 0.963 0.925 0.953 0.821 0.811 0.786 0.803 0.636
aMeasures of diagnostic performance based on manufacturer’s recommendations.
bMeasures of diagnostic performance based on ROC cut-off values. The new cut-off established for each test was: ID Screen® (Positive ≥ Ratio 41.97;
Negative < Ratio 41.97), Leiscan® (Positive ≥ Ratio 0.77; Negative < Ratio 0.77), Leishmania 96® (Positive ≥ Ratio 0.52; Negative < Ratio 0.52) and IFAT (Positive ≥1:160;
Negative <1:160).
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0.985), IFAT (0.926, 95% CI: 0.886 to 0.966) and Speed
Leish K® (0.818, 95% CI: 0.757 to 0.878). In relation to the
classification system proposed by Swets [13], all tests had
high accuracy (0.9 < AUC-ROC ≤ 1) except Speed Leish K®
that was classified as moderately accurate (0.7 < AUC-
ROC ≤ 0.9) (Figure 1).
Statistically significant differences (p < 0.05) were
found between the AUC-ROCs of the quantitative sero-
logical tests (IFAT, ID Screen®, Leiscan® and Leishmania
96®) and the only qualitative rapid test evaluated (Speed
Leish K®). There were also statistically significant differ-
ences between AUC-ROCs of the ELISAs (ID Screen®
and Leiscan®) and the IFAT (p < 0.05). However, there
was no statistical difference between the AUC-ROCs of
Leishmania 96® and IFAT (p > 0.05).
Table 1 shows the results of measures of diagnostic per-
formance parameters based on the AUC-ROC curve cut-
off values for the quantitative serological test studied.
Dogs
Table 3 shows the results of measures of diagnostic per-
formance (sensitivity and specificity) for each group
studied based on the manufacturer’s recommendations
for the serological tests evaluated.
Clinically sick infected dogs (n = 36)
The IFAT was positive for all dogs in the group. The
commercial tests analyzed obtained a negative result inTable 2 Positive predictive value (PPV) and negative predictiv
(25%) or low seroprevalence settings (10%)
ID screen® Leis
PVV
High seroprevalence setting (25%) 1.000 1.0
Low seroprevalence setting (10%) 1.000 1.0
NPV
High seroprevalence setting (25%) 0.985 0.9
Low seroprevalence setting (10%) 0.995 0.9some animals: Speed Leish K® (3/36), Leiscan® (1/36), ID
Screen® (1/36) and Leishmania 96® (1/36). One dog was
classified as negative by all commercial serological tests
while found as high positive by the UAB in house ELISA
and positive by IFAT (antibody titer of 1:40). This dog
was classified as stage IV based on LeishVet guidelines
[2,3] and was confirmed by positive blood and bone
marrow real time PCR [9]. Speed Leish K® conflicting re-
sults (n = 3) were classified as medium positive (n = 1)
and high positive (n = 2) by the UAB in house ELISA.
Clinically healthy infected dogs (n = 18)
A higher number of dogs in this group had negative re-
sults depending on the serological test evaluated: IFAT
(1/18), ID Screen® (3/18), Leiscan® (6/18), Leishmania 96®
(7/18) and Speed Leish K® (15/18). With respect to the
quantitative tests evaluated, all the samples with conflict-
ing serological results were classified as low positive by
the UAB in house ELISA, differently from the Speed Leish
K® conflicting sample results (n = 15) which were classified
as low positive (n = 11), medium positive (n = 1) and high
positive (n = 3) by the UAB in house ELISA.
Seropositive infected dogs with low to high levels of
anti-Leishmania antibodies (n = 53)
All dogs in this group were positive using the Leish-
mania 96®. However, some of the dogs in this group
were negative by the Leiscan® and ID Screen® (1/53),
IFAT (13/53) and the rapid test Speed Leish K® (21/53).e value (NPV) of each serological test based on high
can® Leishmania96® IFAT Speed Leish K®
00 0.748 0.777 1.000
00 0.497 0.538 1.000
76 0.973 0.955 0.892
92 0.991 0.984 0.961
Figure 1 AUC-ROC curve analysis of each serological test studied based on manufacturer’s recommendations.
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(n = 1) were classified as low positive by the UAB in
house ELISA. IFAT results (n = 13) were classified as
medium positive (n = 9) and high positive (n = 4) and, fi-
nally, Speed Leish K® results (n = 21) were classified as
low positive (n = 5), medium positive (n = 11) and high
positive (n = 5) by the UAB in house ELISA.Uninfected dogs from non-endemic area (n = 50)
Three dogs were positive based on IFAT with an anti-
body titer of 1:40. All dogs were seronegative for the
other serological tests studied.Table 3 Results of measures of diagnostic performance (sensi
the manufacturer’s recommendations of serological tests
Groups Measu
Clinically sick infected dogs (n = 36)
Sensitiv
Clinically healthy infected dogs (n = 18)
Seropositive infected dogs
High antibody levels (n = 34)
Medium antibody levels (n = 14)
Low antibody levels (n = 5)
Total (n = 53)
Uninfected dogs from non-endemic area (n = 50)
SpecificUninfected dogs from endemic areas (n = 32)
Dogs seropositive to other pathogens (n = 14)Uninfected dogs from endemic areas (n = 32)
Two dogs were positive based on IFAT (titer 1:40), whereas
for the Leishmania 96® ELISA test, 4 dogs had a positive re-
sult (4/32). All dogs were negative for the other serological
tests studied.
Dogs seropositive to other pathogens (n = 14)
The ID screen®, Leiscan® and Speed Leish K® where
highly specific and no dogs within this group had a posi-
tive result with these tests. For the IFAT test, 3 dogs
were positive for L. infantum antigen (antibody titers of
1:40 and 1:80) with sera positive against different patho-
gens: A. phagocytophilum (antibody titer of 1:640), E.tivity and specificity) for each group studied based on
res ID screen® Leiscan® Leishmania 96® IFAT Speed Leish K®
ity
0.972 0.972 0.972 1.000 0.917
0.833 0.667 0.611 0.944 0.167
1.000 1.000 1.000 0.882 0.853
1.000 1.000 1.000 0.357 0.214
0.800 0.800 1.000 1.000 0.000
0.981 0.981 1.000 0.750 0.604
ity
1.000 1.000 1.000 0.940 1.000
1.000 1.000 0.875 0.938 1.000
1.000 1.000 0.571 0.786 1.000
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titer of 1:1280).
The test with the highest positive results was Leishmania
96® (n = 6). Sera positive for E. canis (n = 2 with titers ran-
ging from 1:640–1:1280), R. conorii (n = 3 with titers ranged
from 1:640–1:1280) and T. gondii (n = 1 with an antibody
titer of 1:640) were all positive for L. infantum antigen with
this test. However, all positive results were low.
Using Speed Leish K® as a screening test for CaniLeish®
prevaccination
In the present study, some canine sera that were negative
by the Speed Leish K®, were positive based on quantitative
serological techniques. 31 dogs were positive with the
Leiscan® and 41 were positive by the Leishmania 96® but
negative with the Speed Leish K®. With ID Screen®, 34
positive dogs were found to be negative using the Speed
Leish K®. For IFAT, 38 positive dogs were negative using
the Speed Leish K®. Thirty six percent of infected dogs
(39/107) were considered negative by this test. Of the 107
infected dogs, a total of 18 (16.82%) with a positive result
by all quantitative serological tests were classified as sero-
negative based on the Speed Leish K®. These dogs had false
negative results by this rapid test. Table 4 describes num-
ber of seropositive animals and antibody levels based on
the UAB in house ELISA and IFAT of dogs classified as
seronegative by the Speed Leish K®.
Discussion
Serological methods such as IFAT, ELISA and rapid tests
are amongst the most common diagnostic techniques
employed in clinical and research studies on canine L.
infantum infection [3,16]. For both IFAT and ELISA, quan-
tification using antibody titer or optical density allows clas-
sification of antibody levels against L. infantum antigen.
The IFAT technique has traditionally been considered a
gold standard for the serological diagnosis of L. infantum
infection, with optimal performance measures with regards
to sensitivity and specificity [14]. This test is still considered
by some authors to be a technical reference in diagnostic
laboratory practices [17]. However, its interpretation can be
subjective depending on the operator’s skills and experience
when interpreting results [15]. The ELISA technique allows
use of different kinds of antigens. These antigens can beTable 4 Number of seropositive dogs and antibody levels (UA
seronegative by the Speed Leish K®
UAB in house ELISA Low positive Medium
N° dogs
(% positivity; Mean ± SD) 16 (87.86 ± 32.23) EU 13 (228.21
ELISA Unit (EU)
Titers IFAT 1:40 1:
N° dogs 6 8classified into four groups according to their nature: whole
or soluble extracts of promastigotes, whole or soluble ex-
tracts of amastigotes, recombinant proteins and purified
proteins. The sensitivity and specificity of the ELISA tech-
nique varies depending on which antigen is used [16,18].
The use of amastigotes as antigen appears to be more sensi-
tive than promastigote antigen for detection of antibodies
in both sick and subclinical dogs [19]. In the present study,
the serological techniques with better diagnostic perform-
ance measures were found to be the quantitative ELISAs.
The performance measures for ELISA sensitivity ranged
from 0.925 to 0.953 and specificity ranged from 0.869 to
1.000. The IFAT technique obtained a sensitivity of 0.869
and a specificity of 0.917. These results are similar to those
in other published studies [18,20]. It is noteworthy that,
apart from the UAB in house ELISA test, IFAT was the only
one test able to detect all the subjects belonging to the
group of clinically sick infected dogs (36/36) and almost all
the ones belonging to the group of clinically healthy in-
fected dogs (17/18). The worst performances of IFAT were
observed in the group of seropositive infected dogs with
medium to high levels of anti-Leishmania antibodies (13/53
false negative results) but it is important to note that this
group of dogs were classified based only on a quantitative
UAB in house ELISA precluding a possible certain diagnos-
tic performance bias although not likely due to the fact the
high antibodies levels are associated with parasite dissemin-
ation and clinical illness [1]. Another limitation of IFAT (at
the cut-off of 1:40) was an imperfect specificity observed in
the group of uninfected dogs from non-endemic area (3/
50) but also in dogs seropositive to other pathogens (2/32)
possibly due to cross-reactions with other pathogens such
as A. phagocytophilum, E. canis and R. conorii.
The use of ROC curve analysis as an analytical tool in
comparative studies of diagnostic tests is quite widespread,
however, its use in veterinary studies has been less com-
mon than in human research. The main advantage of this
type of analysis is to select the most optimal cut-off [21].
In this study, the ROC curve analysis managed to improve
the performance measures of ELISAs: ID Screen® and Leis-
can®. A new cut-off established for Leishmania 96® and the
in house IFAT produced an increase in specificity; however,
this was at the expense of reduced sensitivity. Finally, the
ROC curve cannot provide a cut-off that will maximizeB in house ELISA and IFAT) of those classified as
positive High positive
± 50.93) EU 10 (327.51 ± 36.93) EU
80 1:160 1:320 1:2560
13 1 2
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http://www.parasitesandvectors.com/content/7/1/111performance measures for the rapid Speed Leish K® test, in
which the result is a dichotomous variable.
Immunochromatographic rapid tests such as Speed
Leish K® have many advantages: they are easy to interpret,
quick to use and do not require sophisticated equipment
and so may be ideal for use in clinical practice. However,
the rapid test only provides a qualitative result and the
majority of the times requires confirmation with a quanti-
tative serological test which may increase the cost of diag-
nosis. Diagnosis using a quantitative serological technique
is always advisable as it provides more information regard-
ing antibody level [2,3]. The Speed Leish K® showed high
specificity with a value of 1.000 in this study, however, sen-
sitivity was low (0.636). A previous study has shown that
qualitative rapid tests have low sensitivity in infected sub-
clinical dogs [18] and this was also demonstrated in this
study.
A study published by Ferroglio et al. [6] evaluated a total
of 250 samples, of which 125 were negative and 125 were
positive to L. infantum infection determined by IFAT. Of
the 125 positive samples, 81 samples were strongly posi-
tive (antibody titers ≥ 1: 160) and 44 samples showed low-
reactivity (antibody titers of 1:40 or 1:80). Samples with a
titer of 1:40 and 1:80 by IFAT were evaluated again with
Western Blot (WB) because it is considered a more sensi-
tive technique than IFAT [22]. In this study, the sensitivity
and specificity for Speed Leish K® were 0.963 and 1.000
based on strongly positive and negative samples by IFAT.
In the case of samples with borderline results for IFAT
(antibody titers of 1:40 or 1:80), when WB was considered
the reference technique, Speed Leish K ® showed a sensi-
tivity and specificity of 0.975 and 1.000, respectively for
sera with antibody titers of 1:80. For sera with IFAT titers
of 1:40, the sensitivity of Speed Leish K ® was 0.533 and
the specificity was 1.000. This study has found that dogs
with a low level of anti-Leishmania antibodies may not be
detected correctly by the rapid test Speed Leish K® [6] in
agreement with the present results of this study. In the
present study, Speed Leish K® detected only 3 dogs out of
18 seropositive infected healthy dog group. This study has
also shown that Speed Leish K® failed to detect infected
dogs (39/107). In addition, a total of 18 out of 107 infected
dogs (16.82%) with a positive result by all quantitative
serological tests were classified as seronegative based on
Speed Leish K®. Moreover, Speed Leish K® did not detect
three sick infected dogs. It is important to highlight that a
screening serological test should have a good sensitivity.
Therefore, the Speed Leish K® does not seem to have a
good diagnostic performance as a screening serological
test.
The Speed Leish K® has been recommended for prevac-
cination screening for L. infantum infection before use of
the CaniLeish® vaccine. The manufacturers recommend
vaccination of those dogs with a negative Speed Leish K®result. The efficacy of the vaccine has been evaluated ex-
clusively on negative Leishmania dogs and therefore its
use is limited to non-infected seronegative healthy dogs
[23]. The results of this study demonstrate that the Speed
Leish K® test has low sensitivity. The use of this test may
result in vaccinating dogs that are infected with L. infan-
tum and seropositive or even sick but that appear sero-
negative based on the rapid test Speed Leish K® as
demonstrated in the present study. The consequences of
immunizing seropositive dogs are unknown, but there is a
risk that some vaccinated seropositive dogs could develop
clinical leishmaniosis. In addition, the incorrect diagnosis
of infected dogs may have important implications for Vet-
erinary Medicine and Public Health that should be consid-
ered. Future studies should further characterize the
efficacy and possible implications of vaccination of sero-
positive dogs.
A study [20] evaluated the Leiscan® test and obtained
good performance measures of sensitivity and specificity of
0.980 and 1, respectively, similar to those described in the
present study (sensitivity of 0.925 and specificity 1). The
main difference between the two studies is the type of sam-
ple used. The dogs studied in the cited article were experi-
mentally infected intravenously with a high dose of
promastigotes [20], whilst the present study enrolled unin-
fected and naturally infected dogs. The evolution and
pathogenesis of natural infection is highly variable and not
easily comparable with experimental infection. It should be
pointed out that the administration of intravenous parasites
for experimental infection induces a high production of
anti-Leishmania antibody levels, and a rapid progression of
clinical signs and lesions when compared to experimental
intradermal infection [24]. It is known that naturally sick
infected dogs have higher production of antibodies directed
to a greater number of antigenic epitopes [25,26] and these
antibodies are more easily detectable by a serological test,
compared to subclinical infected dogs in which the produc-
tion of antibodies and the number of antigenic epitopes to
which the immune system responds is lower. For this rea-
son, it is important to note that there may also be differ-
ences between experimental and natural infections in the
degree and type of antibody production.
The Leishmania 96® has also been evaluated in other
studies [27]. Both sensitivity (88.9% versus 92.5% of
this study) and specificity (78.2% versus at 89.6% in the
present study) are mildly different with better diagnos-
tic performance in the present study. A possible ex-
planation for the difference in both sensitivity and
specificity between the two studies could be the use of
a single serological method as a reference test and poor
characterization of dogs in the previous study. The
good sensitivity and specificity of ID Screen® in the
present study are very similar to those found in a pre-
vious study [28].
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the possibility of cross-reaction phenomenon against
other pathogens or other clinical entities [19,29]. A total
of 14 samples from animals diagnosed by the IFAT tech-
nique with a positive result to other pathogens were se-
lected for this study to determine specificity. The only
serological tests that had a specificity of 100% were the
Leiscan®, ID Screen® and Speed Leish K®, whilst other
tests studied showed some cross-reactions with E. canis,
A. phagocytophilum, R. conorii and T. gondii. This cross-
reactivity phenomenon against other pathogens such as
E. canis, Babesia canis, T. gondii, Neospora caninum and
Hepatozoon canis has been sporadically described in
other studies [19,29,30]. Cross-reactivity with L. infan-
tum is more common in infection of dogs with other
species of Leishmania or with other protozoans such as
Trypanosoma cruzi, which are prevalent in America and
not in Europe [31,32]. Cross-reactions typically result in
false positive results with low antibody levels [19] in
agreement with the results of the present study.
The absence of a diagnostic reference or gold standard
results in the combination of one [27], two [33] or more
diagnostic tests [29] used as “gold standard” in several
studies from which new techniques can be compared. A
problem associated with this lack of “gold standard” is that
a standardization of results is not possible, which means
that comparison of results between studies is difficult. In
addition, there is a clear tendency in many studies to select
only sick dogs with clinical signs and there are limited
studies with descriptions of clinical staging and severity of
illness, thus, an imbalance between studies on infected
sick dogs and subclinical infected dogs exist [19,34]. This
type of approach can lead to obtaining higher values of
diagnostic performance measures than would be achieved
with more heterogenous dog groups. In the present study,
we used the new clinical classification previously described
[2,3] and, in addition, all sick dogs presented at least mod-
erate disease based on the LeishVet clinical staging [3].
Moreover, we studied different states of infection of dogs.
In future comparative studies of diagnostic and serological
tests, it would be advisable to include other independent
diagnostic tests as a reference; namely quantitative real-
time PCR (RT-PCR) or assessments of the cellular im-
munity test as we did in some groups in the present study.
Conclusions
This study demonstrated that all serological techniques
showed high specificity. However, sensitivity varied from
one technique to another. The Leiscan® and ID Screen®
tests had superior diagnostic performance measures com-
pared to the IFAT, but among the tests evaluated in the
present study, IFAT was the most sensitive test for the
confirmation of clinically sick infected dogs. All the quan-
titative serological tests were superior when compared tothe only qualitative rapid test evaluated (Speed Leish K®).
The use of Speed Leish K® as a screening test prior to the
use of the vaccine CaniLeish® may not be appropriate as
sensitivity was found to be substantially lower than for the
quantitative ELISAs and IFAT. This may lead to the vac-
cination of seropositive dogs and in some cases seroposi-
tive sick dogs.
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